Brief: BioAtla Announces Clinical Collaboration With Bristol Myers Squibb To Study Mecbotamab Vedotin (Ba3011) And Ozuriftamab Vedotin (Ba3021) In Combination With Opdivo® (Nivolumab) For Treatment Of Solid Tumors

Bioatla

10/01/2022 23:28

Jan 10 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * BIOATLA ANNOUNCES CLINICAL COLLABORATION WITH BRISTOL
MYERS
SQUIBB TO STUDY MECBOTAMAB VEDOTIN (BA3011) AND OZURIFTAMAB
VEDOTIN (BA3021) IN COMBINATION WITH OPDIVO® (NIVOLUMAB) FOR
TREATMENT OF SOLID TUMORS
    * BIOATLA INC - BIOATLA WILL SERVE AS STUDY SPONSOR AND WILL
BE
RESPONSIBLE FOR COSTS ASSOCIATED WITH TRIAL EXECUTION
    * BIOATLA INC - BRISTOL MYERS SQUIBB WILL PROVIDE OPDIVO
CLINICAL
DRUG SUPPLY FOR STUDY

Source text for Eikon:  ID:nPn2sPkhka 
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))